Sorry, you need to enable JavaScript to visit this website.
Skip to main content

KRAS gene mutation detection

KRAS gene mutation detection

Kirsten rat sarcoma viral proto-oncogene homologue also known as KRAS plays an important role in regulating the epidermal growth factor receptor (EGFR) pathway. Somatic KRAS mutations occur frequently in non small cell carcinoma (16-38%), Colorectal carcinoma (30-40%) and pancreatic cancer (˃90%). It is activated by point mutations resulting in single amino acid substitutions in codons 12, 13 and 61. Mutations in KRAS codon 12 and 13 have been shown as a clinical tool to discriminate at a high level of significance between responder and non responders especially in patients with metastatic colorectal cancer receiving the EGFR inhibitors cetuximab and panitumumab. Recent evidence demonstrated that patients with metastatic CRC whose tumors are Carriers of the wild type version of the KRAS gene are much more likely than patients with the mutant form of the gene to benefit from treatment.

Last updated on : January 12, 2023 3:19am